Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors

European Journal of Cancer

Volumn 46, Issue 9, 2010, Pages 1537-1553

  Patel, Roshani R ^a,b   Sengupta, Surojeet ^b,c   Kim, Helen R ^b,c   Klein Szanto, Andres J ^b   Pyle, Jennifer R ^b   Zhu, Fang ^b   Li, Tianyu ^b   Ross, Eric A ^b   Oseni, Salewa ^b   Fargnoli, Joseph ^d   Jordan, V Craig ^b,c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiogenesis; Breast cancer; Brivanib alaninate; Hormone resistance; Tamoxifen; VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; BRIVANIB ALANINATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FULVESTRANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ALANINE; ANTINEOPLASTIC AGENT; BRIVANIB; FGFR1 PROTEIN, HUMAN; PYRROLE DERIVATIVE; TRIAZINE DERIVATIVE; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ENDOMETRIUM CANCER; FEMALE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; HUMAN; METABOLISM; NUDE MOUSE; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XENOGRAFT;

ALANINE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; RANDOM ALLOCATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77952572232     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.018     Document Type: Article

References (60)

1. Folkman J. Angiogenesis. Annu Rev Med 57 (2006) 1-18
2. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 6 (2007) 273-286
3. Naumov G.N., Akslen L.A., and Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5 (2006) 1779-1787
4. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
5. Jain R.K., and Carmeliet P.F. Vessels of death or life. Sci Am 285 (2001) 38-45
6. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
7. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26 (2008) 1948-1955
8. Muss H.B., Tu D., Ingle J.N., et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26 (2008) 1956-1964
9. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26 (2008) 1965-1971
10. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 (2004) 207-213
11. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
12. Crivellari D., Sun Z., Coates A.S., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26 (2008) 1972-1979
13. Takei H., Lee E.S., and Jordan V.C. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9 (2002) 39-42
14. Hyder S.M., Nawaz Z., Chiappetta C., et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60 (2000) 3183-3190
15. Hyder S.M. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat Cancer 13 (2006) 667-687
16. Hyder S.M., Stancel G.M., Chiappetta C., et al. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 56 (1996) 3954-3960
17. Kirk E. Dog's tale of survival opens door in cancer research. USA Today 2002. Available from: http://www.usatoday.com/news/health/2002-07-24-cover-cancer_x.htm.
18. Blackwell K.L., Haroon Z.A., Shan S., et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6 (2000) 4359-4364
19. Ferrara N., Hillan K.J., Gerber H.P., et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 (2004) 391-400
20. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
21. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
22. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
23. Eskens F.A., and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42 (2006) 3127-3139
24. Huynh H., Ngo V.C., Fargnoli J., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14 (2008) 6146-6153
25. Bhide R.S., Cai Z.W., Zhang Y.Z., et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49 (2006) 2143-2146
26. Rosen L.S., Wilding G., Sweeney C., et al. Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol 24 (2006) 3051
27. Jonker D.J., Rosen L.S., Sawyer M., et al. A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol 25 (2007) 3559
28. Gottardis M.M., Robinson S.P., and Jordan V.C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30 (1988) 311-314
29. O'Regan R.M., Cisneros A., England G.M., et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth. J Natl Cancer Inst 90 (1998) 1552-1558
30. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48 (1988) 812-815
31. O'Regan R.M., Gajdos C., Dardes R.C., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94 (2002) 274-283
32. Gottardis M.M., and Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48 (1988) 5183-8187
33. Robinson S.P., and Jordan V.C. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49 (1989) 1758-1762
34. Stossi F., Barnett D.H., Frasor J., et al. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER)α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145 (2004) 3473-3486
35. Gowri P.M., Sengupta S., Bertera S., et al. Lipin1 regulation by estrogen in uterus and liver: implications for diabetes and fertility. Endocrinology 148 (2007) 3685-3693
36. Frasor J., Danes J.M., Komm B., et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 (2003) 4562-4574
37. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 25 (2001) 402-408
38. Cai Z.W., Zhang Y., Borzilleri R.M., et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51 (2008) 1976-1980
39. O'Regan R.M., Osipo C., Ariazi E., et al. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 12 (2006) 2255-2263
40. Dardes R.C., O'Regan R.M., Gajdos C., et al. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. Clin Cancer Res 8 (2002) 1995-2001
41. Rosenbaum-Dekel Y., Fuchs A., Yakirevich E., et al. Nuclear localization of long-VEGF is associated with hypoxia and tumor angiogenesis. Biochem Biophys Res Commun 332 (2005) 271-278
42. Qu Z., Van Ginkel S., Roy A.M., et al. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res 68 (2008) 6232-6240
43. Aesoy R., Sanchez B.C., Norum J.H., et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 6 (2008) 1630-1638
44. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008) 1810-1816
45. Kranz A., Mattfeldt T., and Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84 (1999) 293-298
46. Scherbakov A.M., Lobanova Y.S., Shatskaya V.A., et al. Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?. Breast Cancer Res Treat 100 (2006) 1-11
47. Weigand M., Hantel P., Kreienberg R., et al. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8 (2005) 197-204
48. Ryden L., Linderholm B., Nielsen N.H., et al. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82 (2003) 147-154
49. Pink J.J., and Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56 (1996) 2321-2330
50. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009) 220-231
51. Ebos J.M., Lee C.R., Cruz-Munoz W., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009) 232-239
52. Reynolds A.R., Hart I.R., Watson A.R., et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 1 (2009) 392-400
53. Ebos J.M., Lee C.R., and Kerbel R.S. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15 (2009) 5020-5025
54. Jordan V.C., Lewis-Wambi J., Kim H., et al. Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 16 (2007) S105-S113
55. Jordan V.C., Lewis-Wambi J.S., Patel R.R., et al. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast 18 (2009) S10-S17
56. Lonning P.E., Taylor P.D., Anker G., et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 (2001) 111-116
57. Ellis M.J., Gao F., Dehdashti F., et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302 (2009) 774-780
58. Wolf D.M., and Jordan V.C. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent results in cancer research (1993), Springer-Verlag, Heidelberg p. 23-33
59. Yao K., Lee E.S., Bentrem D.J., et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6 (2000) 2028-2036
60. Ryden L., Stendahl M., Jonsson H., et al. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 89 (2005) 135-143